ES2581843T3 - Terapias probióticas para el autismo - Google Patents

Terapias probióticas para el autismo Download PDF

Info

Publication number
ES2581843T3
ES2581843T3 ES11831629.8T ES11831629T ES2581843T3 ES 2581843 T3 ES2581843 T3 ES 2581843T3 ES 11831629 T ES11831629 T ES 11831629T ES 2581843 T3 ES2581843 T3 ES 2581843T3
Authority
ES
Spain
Prior art keywords
autism
syndrome
bacteria
spectrum disorders
autism spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11831629.8T
Other languages
English (en)
Inventor
Sarkis K. Mazmanian
Paul H. Patterson
Janet Chow
Elaine Hsiao
Sara Mcbride
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology CalTech
Original Assignee
California Institute of Technology CalTech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology CalTech filed Critical California Institute of Technology CalTech
Application granted granted Critical
Publication of ES2581843T3 publication Critical patent/ES2581843T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una composición que comprende una única especie de bacteria para su uso en el tratamiento de un individuo que padece ansiedad, autismo, trastornos del espectro autista, una afección mental con algunos síntomas de trastornos del espectro autista, síndrome de X Frágil, síndrome de Rett, esclerosis tuberosa, trastorno obsesivo compulsivo, síndrome de déficit de atención o esquizofrenia, mediante el cual el individuo muestra un desempeño del comportamiento mejorado, en la que la especie de bacteria es B. fragilis, B. thetaiotaomicron o B. vulgatus.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11831629.8T 2010-10-07 2011-10-06 Terapias probióticas para el autismo Active ES2581843T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39100410P 2010-10-07 2010-10-07
US391004P 2010-10-07
US201161472963P 2011-04-07 2011-04-07
US201161472963P 2011-04-07
PCT/US2011/055159 WO2012048152A2 (en) 2010-10-07 2011-10-06 Probiotic therapies for autism

Publications (1)

Publication Number Publication Date
ES2581843T3 true ES2581843T3 (es) 2016-09-07

Family

ID=45925310

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16164727.6T Active ES2662412T3 (es) 2010-10-07 2011-10-06 Terapias probióticas para el autismo
ES11831629.8T Active ES2581843T3 (es) 2010-10-07 2011-10-06 Terapias probióticas para el autismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES16164727.6T Active ES2662412T3 (es) 2010-10-07 2011-10-06 Terapias probióticas para el autismo

Country Status (15)

Country Link
US (3) US9452189B2 (es)
EP (2) EP3072524B1 (es)
JP (2) JP5931884B2 (es)
CA (1) CA2813606C (es)
CY (1) CY1120119T1 (es)
DK (1) DK3072524T3 (es)
ES (2) ES2662412T3 (es)
HR (1) HRP20180559T1 (es)
HU (1) HUE038600T2 (es)
LT (1) LT3072524T (es)
PL (1) PL3072524T3 (es)
PT (1) PT3072524T (es)
RS (1) RS57006B1 (es)
SI (1) SI3072524T1 (es)
WO (1) WO2012048152A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20110002965A1 (en) * 2007-11-09 2011-01-06 Round June L Immunomodulating compounds and related compositions and methods
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
DK2555753T3 (en) 2010-04-07 2018-11-26 California Inst Of Techn Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems
JP2013530949A (ja) 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
EP3311825A1 (en) 2010-08-04 2018-04-25 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them
EP3072524B1 (en) 2010-10-07 2018-01-17 California Institute Of Technology Probiotic therapies for autism
EP2683390B1 (en) 2011-03-09 2017-05-03 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
US9057070B2 (en) 2011-10-03 2015-06-16 California Institute Of Technology Generation of Bacteriodes fragilis capsular polysaccharide A-only producing mutant strain
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP6679309B2 (ja) * 2012-08-29 2020-04-15 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
US20160120916A1 (en) * 2014-10-30 2016-05-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR20170086492A (ko) * 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
JP6611156B2 (ja) * 2015-01-30 2019-11-27 史郎 栃谷 妊娠期母体腸内細菌攪乱による行動異常モデル動物の作製方法とその用途
AU2016262615C1 (en) 2015-05-14 2021-06-10 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN114366759A (zh) 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
WO2017205302A1 (en) 2016-05-23 2017-11-30 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US20170360848A1 (en) * 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
JP2018047146A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
JP2018047144A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
JP2022514145A (ja) 2018-09-27 2022-02-10 フィンチ セラピューティクス ホールディングス エルエルシー てんかんおよび関連する障害を治療するための組成物および方法
JP7269568B2 (ja) * 2019-07-12 2023-05-09 コンビ株式会社 不安障害及び／又は気分障害を改善又は予防するための組成物
TW202329963A (zh) * 2021-12-21 2023-08-01 國立大學法人大阪大學 類鴉片於治療泛自閉症障礙之用途
CN114699424B (zh) * 2022-02-16 2023-07-18 广州知易生物科技有限公司 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用
CN114699423B (zh) * 2022-02-16 2023-06-23 广州知易生物科技有限公司 脆弱拟杆菌的荚膜多糖提取物在制备防治精神分裂症的药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
JP4372347B2 (ja) 1998-03-11 2009-11-25 あすか製薬株式会社 発泡性腸溶製剤
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
EP1817305A2 (en) 2004-11-16 2007-08-15 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
WO2009055362A1 (en) * 2007-10-26 2009-04-30 Moore Brenda E Probiotic compositions and methods for inducing and supporting weight loss
EP3733642B1 (en) 2007-11-06 2024-05-08 PTC Therapeutics, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009089464A1 (en) 2008-01-09 2009-07-16 Yale University Mutations in contaction associated protein 2 (cntnap2) are associated with increased risk for ideopathic autism
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US9547013B2 (en) 2010-04-29 2017-01-17 Wisconsin Alumni Research Foundation Molecule biomarkers of autism
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
US20130195802A1 (en) 2010-06-01 2013-08-01 Moore Research Enterprises Llc Cellular Constituents From Bacteroides, Compositions Thereof, and Therapeutic Methods Employing Bacteroides or Cellular Constituents Thereof
EP2590658A2 (en) 2010-07-08 2013-05-15 Katholieke Universiteit Leuven Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
EP3072524B1 (en) 2010-10-07 2018-01-17 California Institute Of Technology Probiotic therapies for autism
US20120237482A1 (en) 2011-03-18 2012-09-20 Juan Rodriguez Methods for treatment of neurological disorders by modulation of microglial activation
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR20170086492A (ko) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
US20160120916A1 (en) 2014-10-30 2016-05-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
CN114366759A (zh) 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US10200089B2 (en) 2017-06-07 2019-02-05 General Electric Company Sensor system and method

Also Published As

Publication number Publication date
WO2012048152A3 (en) 2012-06-21
US20210000888A1 (en) 2021-01-07
PT3072524T (pt) 2018-04-23
PL3072524T3 (pl) 2018-06-29
EP3072524A1 (en) 2016-09-28
HRP20180559T1 (hr) 2018-06-01
US9452189B2 (en) 2016-09-27
US20160375065A1 (en) 2016-12-29
DK3072524T3 (en) 2018-04-09
LT3072524T (lt) 2018-03-26
CA2813606A1 (en) 2012-04-12
EP2624863A4 (en) 2014-04-02
SI3072524T1 (en) 2018-04-30
US20120087895A1 (en) 2012-04-12
JP5931884B2 (ja) 2016-06-08
EP3072524B1 (en) 2018-01-17
RS57006B1 (sr) 2018-05-31
US11896629B2 (en) 2024-02-13
HUE038600T2 (hu) 2018-10-29
CA2813606C (en) 2019-01-22
EP2624863A2 (en) 2013-08-14
EP2624863B1 (en) 2016-04-20
ES2662412T3 (es) 2018-04-06
JP2013544780A (ja) 2013-12-19
JP2016185959A (ja) 2016-10-27
JP6177379B2 (ja) 2017-08-09
WO2012048152A2 (en) 2012-04-12
CY1120119T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
ES2581843T3 (es) Terapias probióticas para el autismo
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
CL2014000884A1 (es) Sistema de filtrado que comprende una carcasa del filtro que comprende un orificio de entrada y un orificio de salida, una pluralidad de unidades de filtrado dentro de la carcasa, al menos un sistema de limpieza de al menos una unidad de filtrado, y al menos una unidad de accionamiento para el desplazamiento de una o ambas de entre dichas al menos una unidad y el al menos un sistema de limpieza; mecanismo de transmision.
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
ES2605171T3 (es) Composiciones ansiolíticas que comprenden péptidos derivados de la Caseína ALFAs1
ES2553423T3 (es) Viroterapia oncolítica para el tratamiento del sarcoma de Ewing
ES2535685B1 (es) Vitrina refrigerada
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
ES2529362B1 (es) Bacteria degradadora de microcistina, biofiltro que la incluye así como método de depuración de aguas contaminadas con microcistina empleando el mismo
JP1694292S (ja) 空気清浄機
TH57731B (th) ชุดติดตั้งลิฟต์และวิธีการสำหรับการบำรุงรักษาชุดติดตั้งลิฟต์เช่นนี้
TH102079A (th) ชุดติดตั้งลิฟต์และวิธีการสำหรับการบำรุงรักษาชุดติดตั้งลิฟต์เช่นนี้
TH63941S1 (th) ฐานรองถาดคว่ำจาน
TH40848S1 (th) เครื่องทำให้อากาศบริสุทธิ์
TH41562S1 (th) ท่อไอดี
TH113633S (th) ท่อไอดี
TH41563S1 (th) ท่อไอดี
TH41564S1 (th) ท่อไอดี
TH108622S (th) ท่อไอดี
TH1601001667A (th) องค์ประกอบและวิธีการสำหรับการฆ่าเชื้อและการทำความสะอาดเลนส์สัมผัส
TH113068A (th) กรรมวิธีการผลิตแผ่นขัดโลหะผสมที่มีความสม่ำเสมอของโครงสร้างจุลภาค
UA39818U (uk) Масообмінний апарат
TH128280S (th) ขวด
TH40076S1 (th) เครื่องฟอกอากาศ